The role of c-Kit in the development of
melanoma was studied in line 304/B6 of RET-transgenic mice, in which
melanoma spontaneously develops. In Wv/Wv-RET (304/B6)-transgenic mice, in which c-Kit function was severely impaired, development of
melanoma was strongly suppressed. Although 31 of the 44 original RET-transgenic mice died of rapidly growing
melanoma within 12 months after birth, only 8 of the 44 Wv/Wv-RET-transgenic mice developed slowly growing melanocytic
tumors with a greatly prolonged mean
tumor-free period, 2 of which died of
melanoma at a late stage. Even Wv/+-RET-transgenic mice had a clearly prolonged
tumor-free period and definitely reduced frequency (6 of 61) of
tumor death within 12 months after birth.
Melanin production in the skin of these mice was not strongly impaired, suggesting that c-Kit affects the development of
melanomas in these mice with only minor effects in
melanin production. c-Kit expression in skin soon after birth was promoted in RET-transgenic mice, and c-Kit was expressed at high levels at the benign but not malignant stage of the
tumor. A single injection of anti-c-Kit antibody (ACK2) into RET-transgenic mice soon after birth caused a surprisingly long-lasting suppression of development of
melanoma, greatly prolonging the
tumor-free period, and none of the 28 ACK2-treated RET-transgenic mice died from
tumors at 12 months of age. The c-Kit function needed for
melanin production was also suppressed for an unusually long time in ACK2-treated, RET-transgenic mice. These results suggest that c-Kit can be a unique target molecule for
melanoma treatment.